Bortezomib-induced miRNAs direct epigenetic silencing of locus genes and trigger apoptosis in leukemia

Yu-Yi Chu¹,², Chiuang-Yuan Ko³,⁴,⁷, Shao-Ming Wang⁵,⁸, Pin-I Lin¹,⁸, Han-Ying Wang¹, Wen-Chi Lin⁵, Dong-Yu Wu¹, Lu-Hao Wang¹ and Ju-Ming Wang*¹,²,⁵,⁶

MicroRNAs (miRNAs) have been suggested to repress transcription via binding the 3′-untranslated regions of mRNAs. However, the involvement and details of miRNA-mediated epigenetic regulation, particularly in targeting genomic DNA and mediating epigenetic regulation, remain largely uninvestigated. In the present study, transcription factor CCAAT/enhancer binding protein delta (CEBPΔ) was responsive to the anticancer drug bortezomib, a clinical and highly selective drug for leukemia treatment, and contributed to bortezomib-induced cell death. Interestingly, following the identification of CEBPΔ-induced miRNAs, we found that miR-744, miR-3154 and miR-3162 could target CpG islands in the 5′-flanking region of the CEBPΔ gene. We previously demonstrated that the Yin Yang 1 (YY1)/polycomb group (PcG) protein/DNA methyltransferase (DNMT) complex is important for CCAAT/enhancer binding protein delta (CEBPΔ) gene inactivation; we further found that Argonaute 2 (Ago2) interacts with YY1 and binds to the CEBPΔ promoter. The miRNA/Ago2/YY1/PcG group protein/DNMT complex linked the inactivation of CEBPΔ and genes adjacent to its 5′-flanking region, including protein kinase DNA-activated catalytic polypeptide (PKA-C), minichromosome maintenance-deficient 4 (MCM4) and ubiquitin-conjugating enzyme E2 variant 2 (UBE2V2), upon bortezomib treatment. Moreover, we revealed that miRNA binding is necessary for YY1/PcG group protein/DNMT complex-mediated epigenetic gene silencing and is associated with bortezomib-induced methylation on genomic DNA. The present study successfully characterized the interactions of the miRNA/Ago2/YY1/PcG group protein/DNMT complex and provided new insights for miRNA-mediated epigenetic regulation in bortezomib-induced leukemic cell arrest and cell death.

Cell Death and Disease (2017) 8, e3167; doi:10.1038/cddis.2017.520; published online 9 November 2017

MicroRNAs (miRNAs) are composed of 21–24 RNA nucleotides that regulate multiple genes and cellular functions in tumor progression.¹,² By interacting with members of the Argonaute (Ago) subfamily, miRNAs primarily target homologous sites in the untranslated regions (UTRs) of mRNAs, thereby contributing to translational inhibition or mRNA degradation.³,⁴ Based on the findings of transcriptome analysis, over 70% of gene promoters overlapped with noncoding RNA transcripts, which might serve as miRNAs target sites.⁵,⁶ Although miRNAs primarily mediate post-transcriptional gene silencing (PTGS) in the cytoplasm, recent studies have shown that miRNAs also translocate to the nucleus and interact with promoter DNA, thus inactivating gene expression.⁷ In addition, exogenous small RNAs have been implicated in Ago-mediated histone modification and DNA methylation of gene transcripts⁸–¹⁰ and are known for transcriptional gene silencing (TGS). Argonaute 2 (Ago2) has the most well-established role in RNAi as the catalytic engine that drives mRNA cleavage.¹¹ Ago1 and Ago2 have positively aligned it with a complementary nucleic acid. Previous studies have shown that Importin 8 mediates the nuclear transport of miRNAs and the associated Ago proteins, which regulate chromatin modification.¹²,¹³ However, the consequent effects and mechanisms in response to the miRNA-mediated epigenetic regulation remain largely uninvestigated.

Transcription factors have been suggested to regulate the biogenesis of miRNAs.¹⁴,¹⁵ CCAAT/enhancer binding protein delta (CEBPΔ) is a transcription factor that contributes to cell differentiation, motility and death.¹⁶,¹⁷ The abundance of CEBPΔ is typically low in most cells at normal physiological conditions, but is rapidly induced through external stimuli.¹⁸,¹⁹ However, the biology of miRNAs in response to CEBPΔ activation and consequent effects remain largely unknown. We previously demonstrated that CEBPΔ could serve as a tumor suppressor through the activation of apoptosis and growth arrest in prostate, cervical and breast cancers.¹⁸,²⁰–²² We have also demonstrated that CEBPΔ expression can be attenuated in cancer cells by Yin Yang 1 (YY1)/polycomb group (PcG)/DNA methyltransferase (DNMT)-mediated

¹Institute of Bioinformatics and Biosignal Transduction, National Cheng Kung University, Tainan, Taiwan; ²Department of Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan; ³The Ph.D. Program for Neural Regenerative Medicine, Taipei Medical University, Taipei, Taiwan; ⁴Center for Neurotrauma and Neuroregeneration, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; ⁵Institute of Basic Medical Sciences, National Cheng Kung University, Tainan, Taiwan and ⁶Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
*Corresponding author: J-M Wang, Institute of Bioinformatics and Biosignal Transduction, College of Bioscience and Biotechnology National Cheng Kung University, Tainan 701, Taiwan; Tel: +886 627 575 75 ext 31067; Fax: +886 620 836 63; E-mail: yumingw@mail.ncku.edu.tw
These authors contributed equally to this work as first author.
These authors contributed equally to this work as second author.
Received 01.5.17; revised 02.9.17; accepted 04.9.17; Edited by E Candi
epigenetic regulation. In leukemia, CEBPD was suppressed in the blast crisis phase of chronic myeloid leukemia and acute myeloid leukemia (AML) patients. However, the CEBPD-mediated and detailed regulation, especially in response to anticancer drugs, in leukemia is still an open question.

Bortezomib, the first selective inhibitor of the proteasome to reach clinical trials, causes G2–M cell cycle arrest and apoptosis by blocking the action of the 26S proteasome. Bortezomib has been shown to have in vitro and in vivo activity against a variety of malignancies, including multiple myeloma, chronic lymphocytic leukemia, prostate cancer, pancreatic cancer and colon cancer. A recent study showed that bortezomib enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo. Although the transcription-associated apoptotic activation in response to bortezomib has been suggested, the mechanisms and new insights, especially in PTGS-mediated regulation, remain largely uninvestigated.

In this study, CEBPD-responsive miRNAs were identified in leukemic cells. Moreover, protein kinase DNA-activated catalytic polypeptide (PRKDC), minichromosome maintenance deficient 4 (MCM4) and ubiquitin-conjugating enzyme E2 variant 2 (UBE2V2) genes, which are located in the 5′ upstream region of the CEBPD gene, are important for DNA repair and cell cycle regulation. We found that CEBPD-responsive miR-744, miR-3154 and miR-3162 could bind to the promoter regions of CEBPD and its 5′ upstream genes PRKDC, MCM4 and UBE2V2. In certain types of cancer, CEBPD activity is silenced by the epigenetic regulators YY1, Pcg complex and DNMT via enhanced DNA methylation. Moreover, we further demonstrated that the miRNAs, in response to CEBPD, could interact with Ago2 and contribute to histone and DNA methylation via recruiting the binding of YY1/Pcg protein/DNMT complex. This binding consequently inhibited CEBPD and its 5′ upstream genes PRKDC, MCM4 and UBE2V2. The novel miRNA/Ago2-mediated regulation provided a new insight into bortezomib-induced cell death in leukemic cells.

Results

CEBPD is activated by bortezomib and contributes to bortezomib-induced leukemic cell apoptosis. CEBPD was suggested to respond to many anticancer drugs and to contribute to apoptosis induced by these anticancer drugs. The anticancer drug bortezomib was originally suggested to serve as a proteasome inhibitor and a common therapeutic drug of leukemia. Following the observation that CEBPD was responsive to bortezomib treatment in leukemic cells (Figure 1a and Supplementary Figure S1a), we further examined the effect of bortezomib in the induction of apoptosis and tested the involvement of CEBPD in the bortezomib-induced death of leukemic cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and flow cytometry were performed to examine cell survival and assess the sub-G1 cell population, respectively. Reduced cell viability and increased sub-G1 population and apoptosis of THP-1 and U937 cells were observed upon bortezomib treatment (Figures 1b and c and Supplementary Figure S2). Furthermore, an attenuated apoptotic effect was observed following the depletion of CEBPD in bortezomib-treated THP-1 cells (Figure 1d). Next, we verified the involvement of CEBPD in the induction of apoptosis of leukemic cells. A cell viability assay was performed via a doxycycline (Dox)-inducible CEBPD expression system to verify the proapoptotic role of CEBPD in leukemic cells. As expected, induction of CEBPD could attenuate the viability of THP-1 cells (Figures 2a and b). These data suggested that CEBPD has a proapoptotic role in bortezomib-induced apoptosis of leukemic cells.

CEBPD negatively autoregulates and coordinately inactivates the genes located in the 5′ upstream region of the CEBPD gene. CEBPD is a well-known transcription factor and has been suggested to promote apoptosis through the activation of apoptotic genes. However, the involvement of CEBPD in miRNA regulation and its association with consequent cellular responses, especially in its proapoptotic role, remain poorly understood. We first performed miRNA and mRNA microarray analysis in THP-1 cells to explore the link between CEBPD-regulated miRNAs and mRNAs. Using

---

**Figure 1** CEBP, which contributes to leukemic cell apoptosis, is responsive to bortezomib. (a) Bortezomib increases the expression of CEBP. After treatment with bortezomib (50 nM) for 6 h in THP-1 cells, total RNA and protein lysates were harvested and analyzed using qPCR and western blot analysis. (b) Bortezomib inhibits cell viability. After treatment with bortezomib (50 nM) for 24 h, the viability of leukemic cells (THP-1 and U937) was measured using an MTT assay. (c) Bortezomib induces the growth arrest of leukemic cells. After treating with bortezomib (50 nM) for 24 h, the sub-G1 phase of THP-1 and U937 cells was analyzed by flow cytometry. (d) Attenuated CEBPD reverses bortezomib-reduced cell viability in THP-1 cells. THP-1 cells with the IPTG-inducible CEBPD knockdown system were pretreated with IPTG (500 μM) for 3 h. After treatment with bortezomib (50 nM) for 24 h, cell viability was measured using an MTT assay. The data are presented as the mean ± standard error of experiments performed in triplicate (*P<0.05, **P<0.01, Student’s t-test). NS, not significant.
the public access program miRTar, we explored the correlation between the CEBPD-induced downregulated mRNA (Supplementary Table 1) and upregulated miRNA profiles (Supplementary Table 2). Interestingly, among 490 CEBPD-downregulated mRNAs, 407 (83%) CEBPD-responsive mRNAs were not targeted by CEBPD-responsive miRNAs in their UTRs (Figure 3a and Supplementary Table 3). These findings implied that downregulated mRNAs that respond to CEBPD activation could be regulated via other UTR-independent mechanisms. Recently, miRNAs were suggested to be involved in epigenetic regulation via directly targeting DNA.\textsuperscript{40,41} We found that several top 10-ranked CEBPD-responsive miRNAs showed a binding potential on the 5′-flanking region of the CEBPD gene. As mentioned above, the PRKDC, MCM4 and UBE2V2 genes, which are located in the 5′ upstream region of the CEBPD gene, have a potent role in promoting cell cycle S-phase entry or inhibiting apoptosis.\textsuperscript{34–36} Importantly, we found that exogenously expressing CEBPD could attenuate endogenous CEBPD transcripts (Supplementary Figure S3). Moreover, although the transcription of the PRKDC, MCM4 and UBE2V2 genes was not immediately responsive to bortezomib treatment, their transcription was coordinately attenuated with the inactivation of CEBPD in long-term bortezomib treatment (Supplementary Figure S4). These observations raised our interests to test whether activated CEBPD could upregulate miRNAs to inactivate the transcription of CEBPD itself, and the PRKDC, MCM4 and UBE2V2 genes in bortezomib-treated leukemic cells.

Quantitative PCR results showed that PRKDC, MCM4 and UBE2V2 transcripts were attenuated following the induction of CEBPD after exogenously expressing CEBPD or bortezomib treatment in THP-1 or U937 cells (Figures 3b and c and Supplementary Figure S1b). Meanwhile, by analysis with miRTar program, no putative CEBPD-responsive miRNA seed sequences were predicted in the UTRs of CEBPD, PRKDC, MCM4 and UBE2V2 mRNAs. Surprisingly, the complementary seed sequences of CEBPD-responsive miR-744, miR-3154 and miR-3162 (Supplementary Table 2) were predicted to bind the promoter regions of PRKDC, MCM4 and UBE2V2 genes (Figure 3d). We therefore tested whether PRKDC, MCM4 and UBE2V2 mRNAs could be regulated by these three miRNAs. The results showed that PRKDC, MCM4 and UBE2V2 transcripts were downregulated following the increase of these three miRNAs (Figure 3e and Supplementary Figure S8a). Interestingly, in addition to these three genes, the exogenous expression of CEBPD also attenuated endogenous CEBPD transcripts (Supplementary Figure S3a). The result implied that induction of CEBPD could negatively autoregulate CEBPD transcription in leukemic cells. Furthermore, the loss of CEBPD increased the expression of PRKDC, MCM4 and UBE2V2 upon bortezomib treatment (Figure 3f). The results raised a speculation that CEBPD could be the first responsive gene following bortezomib treatment; moreover, the induction of CEBPD increased the expression of miR-744, miR-3154 and miR-3162. Subsequently, these miRNAs could feedback to suppress the transcription of CEBPD itself and PRKDC, MCM4 and UBE2V2 genes.

CEBPD activates the transcription of miR-744, miR-3154 and miR-3162. To reveal the findings described above, we first examined whether CEBPD could induce miR-744, miR-3154 and miR-3162 transcription by directly activating their promoters. The results showed that exogenous HA/CEBPD and bortezomib treatment could activate miR-744, miR-3154 and miR-3162 transcription in THP-1 and U937 cells (Figures 4a and b and Supplementary Figure S5). Moreover, inactivation of CEBPD attenuated miR-744, miR-3154 and miR-3162 transcripts upon bortezomib stimulation (Figure 4c). In addition, miR-3154 is an intergenic miRNA that has its own promoter. Intragenic miR-744 and miR-3162 belong to two individual genes, MAP2K4 and SNHG11, and overexpressed CEBPD could activate MAP2K4 and SNHG11 expression (Supplementary Figure S7). We next investigated whether CEBPD could directly activate the promoters of the genes encoding miR-744, miR-3154 and miR-3162. We cloned and generated three reporters bearing the promoter regions of these three miRNA locations (Figure 4d, upper panel). The results of the reporter assay showed that exogenously expressing CEBPD could induce the promoter activity of genes encoding the three individual miRNAs (Figure 4d, lower panel). Furthermore, an in vivo DNA binding assay showed that CEBPD could directly bind to the promoter regions of genes encoding miR-744, miR-3154 and miR-3162 (Figure 4e). These results suggested that CEBPD was responsive to bortezomib and directly activated the transcription of miR-744, miR-3154 and miR-3162.

Ago2 interacts with YY1 and binds to promoter regions with the PcG complex and HP-1. Mature miRNAs guide Ago-containing complexes to target partially complementary seed sequences on miRNAs and induce the repression of gene expression at the level of mRNA stability or translation. CEBPD activates the expression of miR-744, miR-3154 and miR-3162 in THP-1 cells. Moreover, our current results showed that the increase of these miRNAs could inactivate the transcription of CEBPD itself and PRKDC, MCM4 and UBE2V2
UBE2V2 genes. Thus, we next dissected the potent mechanism underlying miRNA-mediated transcriptional silencing on genomic DNA (gDNA). The results of the immunoprecipitation assay showed that Ago2, but not Ago1, could specifically associate with YY1 in 293T and THP-1 cells with or without bortezomib treatment (Figures 5a and b). In addition, our previous study showed that the YY1/PcG/DNMT complex can be recruited to CpG islands in the promoter region of the CEBPD gene, and that it is critical for mediating epigenetic silencing of the CEBPD gene.20 Moreover, the putative YY1-binding motifs could also be predicted in the promoter regions of the PRKDC, MCM4 and UBE2V2 genes. Thus, we verified whether Ago2, YY1, the PcG complex and DNMT1 can be recruited to the promoter regions of the CEBPD, PRKDC, MCM4 and UBE2V2 genes using a chromatin immunoprecipitation (ChIP)-quantitative PCR (qPCR) assay. The elevated binding of Ago2, YY1, SUZ12, EZH2 and DNMT1 was observed in the regions of the corresponding primers for the indicated promoters upon bortezomib treatment (Figure 5c). In addition, the binding of
HP-1, leading to heterochromatin formation and inactivation of genes, was also detectable on the promoter regions of CEBPD, PRKDC, MCM4 and UBE2V2 genes (Figure 5c). These results suggested that Ago2 interacts with YY1 and YY1-interacting proteins, including PcG proteins, DNMT1 and HP1, upon bortezomib treatment.

miR-744, miR-3154 and miR-3162 mediate TGF by directly binding gDNA. The partial complementary seed sequences of miR-744, miR-3154 and miR-3162, and the consensus YY1-binding motifs were observed in the promoter region of the CEBPD gene. To dissect the binding scenario of miRNAs and YY1 in epigenetic-mediated gene silencing, several heterologous CEBPD reporters were constructed (Figure 6, upper panel) for evaluating their individual contribution and regulation. The results of the reporter assay showed that bortezomib had no effect on the pGL3-promoter-CEBPD (PC) reporter (1938/−590 CEBPD promoter containing YY1-binding motifs), but significantly repressed the activity of the PC with miRNA binding sites (PCmi) reporter (1938/−590 CEBPD promoter region containing YY1-binding motifs and fused with complementary
seed sequences of miR-744, miR-3154 and miR-3162). Importantly, the activity of the PCmi with mutated YY1 binding sites (PCmiMY) reporter (−1938/−590 CEBPD promoter region containing mutant YY1-binding motifs and fused with complementary seed sequences of miR-744, miR-3154 and miR-3162) was reversed upon bortezomib treatment (Figure 6a). In addition, our previous study demonstrated that YY1 could recruit DNMTs and methylate the CpG islands on the CEBPD promoter.20

Next, to investigate whether miRNAs could affect the DNA methylation status, we recovered the transfected reporters and treated samples with bisulfite, followed by methylation-specific PCR. We found that bortezomib enhanced the DNA methylation in the −1938/−590 CEBPD promoter region of PCmi, but that the methylation effect was significantly reduced in the −1938/−590 CEBPD promoter region of PC and PCmiMY (Figure 6b).

Taken together, these results suggested that miRNAs act as initiators and YY1 functions as an effector protein for the DNA methylation-mediated silencing of CEBPD gene transcription. To further confirm the importance of these miRNAs, we introduced the IPTG-inducible miR-744-, miR-3154- and miR-3162-silencing vectors into THP-1 cells. Following the induction of antagomirs of miR-744, miR-3154 and miR-3162, bortezomib-induced DNA methylation on −1938/−590 CEBPD region of PCmi reporter was lost (Figure 6c and Supplementary Figure S8b). Meanwhile, bortezomib-reduced cell viability and the expression of the potent oncogenes, PRKDC, MCM4 and UBE2V2, were also significantly attenuated (Figures 6d and e). The results suggested the importance of the miR-744, miR-3154 and miR-3162-mediated autoregulation of the CEBPD gene and the inactivation of PRKDC,
MCM4 and UBE2V2 genes on bortezomib-induced cell viability.

Discussion

The abundance of CEBPD could be regulated via P38/CREB pathway-upregulated transcriptional activation and RNA-binding protein HuR-stabilized CEBPD mRNA. A previous study showed that bortezomib promotes the shuttling of HuR proteins to the cytoplasm and increases the translation efficiency of its downstream target genes in cancer cells.

In addition, a recent study demonstrated that tyrosine kinase Src could downregulate CEBPD protein stability through the activation of SIAH2 E3 ubiquitin ligase. Moreover, the activation of Src kinase is inhibited by the oncoprotein BCR-ABL in leukemic cells. However, the mechanism(s) underlying bortezomib-induced CEBPD expression in leukemic cells remain an open question and require further examination.

In this study, we found that the potent tumor suppressor CEBPD is responsive to the anticancer drug bortezomib in leukemic cells (Figure 1a). Interestingly, the inactivation of the
PRKDC, MCM4 and UBE2V2 genes occurred in parallel with a decrease in CEBPD transcription (Supplementary Figure S4). Importantly, the inactivation of these four genes followed the increase in CEBPD-responsive miR-744, miR-3154 and miR-3162 expression (Figure 3f and Supplementary Figure S6). Here, we proposed a scenario that CEBPD, which is transiently induced by bortezomib, activates the transcription of miR-744, miR-3154 and miR-3162. Ago2 could further shuttle these three miRNAs into the nucleus and target the promoter regions of genes bearing the seed sequences complementary to these miRNAs. Moreover, the initiator miRNAs/Ago2 complex interacts with YY1 and recruits the epigenetic regulators, PcG complex/DNMTs, to inactivate the transcription of genes, including CEBPD, PRKDC, MCM4 and UBE2V2 (Figure 7).

MCM4 is a proliferation marker and a member of the six minichromosome maintenance proteins and is essential for the origins of DNA replication before the S phase. Accumulating evidence suggests that MCM4 contributes to the proliferation of non-small-cell lung cancer cells. The PRKDC gene is adjacent to the chromosome and has a key role in non-homologous end joining. The expression level of PRKDC was elevated in neuroblastoma patients, associated with poor prognosis and advanced tumor grade. Moreover, the DNA repair gene UBE2V2 acts as a prognostic marker in breast cancer. A previous study suggested that attenuated UBE2V2 increases the cytotoxic effects of UV-induced DNA damage. Accumulating results have indicated that miRNAs could function as tumor suppressors in leukemia. Combined with the observations that CEBPD triggers growth arrest, participates in the bortezomib-induced cell death (Figures 1d and 2b) and activates miR-744, miR-3154 and miR-3162, we further provided a novel mechanism that miRNAs serve as tumor suppressors by eliciting DNA methylation on gDNA in leukemic cells. This study also demonstrates for the first time that CEBPD activation induces leukemic cell death by suppressing a cluster of potent oncopgenes via responsive miRNA-mediated epigenetic silencing. In addition to miR-744, miR-3154 and miR-3162, several CEBPD upregulated miRNAs, including miR-150, miR-142 and miR-29a/b, were suggested to prevent leukemia progression. Additionally, another CEBPD-responsive miR-744 was suggested to act as a tumor suppressor in various cancers, resulting in chromosomal instability and oncogene inactivation. Consistently, these CEBPD-responsive miRNAs further agree with the involvement of CEBPD in promoting cell differentiation and apoptosis.

CEBPd has been suggested to positively regulated peroxisome proliferator-activated receptor-γ (PPARγ) transcription and protein expression in vascular smooth muscle cells and cancer cells. Moreover, the activation of PPARγ could suppress protein expression and transcription of CEBPD via the inactivation of signal transducer and activator of transcription 3 in vascular smooth muscle cells. Additionally, another CEBPD-responsive miR-744 was suggested to act as a tumor suppressor in various cancers, resulting in chromosomal instability and oncogene inactivation. Consistently, these CEBPD-responsive miRNAs further agree with the involvement of CEBPD in promoting cell differentiation and apoptosis.

The highly evolutionarily conserved Ago proteins bind to non-coding RNA and have an essential role in miRNA-mediated post-transcriptional regulation. Accumulating evidence has demonstrated that Ago proteins are present in the nuclear fraction of human cells. Several reports have shown that Ago proteins form a complex with INRNA and bind to genomic DNA, thereby inducing direct TGS. Additionally, Ago1 has been implicated in the YY1/Suz12/Dicer1 complex-mediated repression of the NFI-A gene via competing RNA polymerase II binding. Ago2 was also suggested to interact with the transcriptional repressor, SETDB1, for the repression of gene activation. In the present study, we provided the first evidence that Ago2, but not Ago1, Ago3 or Ago4, interacts with YY1 and binds to gDNA, and that these interactions further recruit the epigenetic regulators PcG proteins and DNMTs to direct TGS (Figure 5). The results also implied that Ago1 and Ago2 have distinct roles, at least in part, to independently contribute to PcG protein- and DNMT-mediated epigenetic regulation.

Figure 7 Schematic model for CEBPD turned off the locus genes and resulted in leukemic cell death through miRNA/Ago2/YY1/PcG group protein/DNMT complex-directed epigenetic silencing. In response to the antitumor drug bortezomib, the transcription factor CEBPD is activated and transcriptionally activates miR-744, miR-3154 and miR-3162. These miRNAs form a complex with Ago2 and translocate into the nucleus to target their complementary DNA sequence-binding sites on the promoter regions of CEBPD, PRKDC, MCM4 and UBE2V2. The initiator miRNAs/Ago2 complex interacts with YY1 and recruits the epigenetic regulators, the PcG complex/DNMTs, to silence the four gene loci, including CEBPD itself. The inactivation of these potent oncopgenes, PRKDC, MCM4 and UBE2V2 result in leukemic cell death via CEBPD-responsive miRNA-mediated epigenetic silencing.
Furthermore, the PcG complex and HP-1 interact and contribute to the silencing effects at the nuclear periphery. Our results showed the binding of HP-1 and the PcG complex on the promoter regions of CEBPD and its 5′ upstream genes (Figure 5c). A previous study showed that Ago1 is dispersed throughout the nuclear interior, whereas Ago2 is localized in the inner nuclear periphery, implying that this area is a transcriptionally repressive compartment. Our study raised several important issues: (1) the location of HP-1 associates with Ago1 and Ago2 distribution in the cell nucleus, (2) the location of miRNAs on gDNA associates with Ago1 and Ago2 and (3) the annotation of miRNAs associated with the cell location of miRNAs on gDNA associates with Ago1 and Ago2.

Materials and Methods

Materials. The TRIsure RNA extraction reagent, Opti-MEM medium, SuperScript III, Dulbecco’s modified Eagle’s medium and Roswell Park Memorial Institute medium were purchased from Invitrogen (Carlsbad, CA, USA). Fetal bovine serum (FBS) was purchased from HyClone Laboratories (Logan, UT, USA). SensiFAST SYBR was purchased from Bioline (Taunton, MA, USA). A luciferase assay system was purchased from Promega (Madison, WI, USA). The α-tubulin antibody (T6199) was purchased from Sigma (St. Louis, MO, USA), and antibodies against CEBPD (SC-636), Ago2 (sc-32877), Ago3 (sc-32862), Ago4 (sc-374220) and YY1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-Ago1 antibody (no. 07-599) was purchased from Millipore (Billerica, MA, USA). The anti-SUZ12 antibody was purchased from Abcam (Cambridge, UK). The anti-DNMT1 antibody was purchased from IMGENEX (San Diego, CA, USA). All oligonucleotides were synthesized at MDBio Inc. (Taipei, Taiwan).

Cell culture. The human monocytic leukemia cell line THP-1 and the human myeloid cell line U937 were maintained in Roswell Park Memorial Institute medium supplemented with 10% FBS, 100 μg/ml streptomycin and 100 U/ml penicillin. The human embryonic kidney cell line 293T and human epithelial cells Amphi were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS, 100 μg/ml streptomycin and 100 U/ml penicillin.

Reverse transcription-polymerase chain reaction. THP-1 cells were treated with Dox or bortezomib. Total RNA was extracted using TRIsure. The isolated RNA was subjected to reverse transcription using SuperScript III for cDNA synthesis. The following oligonucleotide primers were used in the qPCR analysis: GAPDH (F): 5′-CCACCCGAGACTGATGTAT-3′ and GAPDH (R): 5′-TTTACGTCAGGGATACCC-3′; CEBPD (F): 5′-GCCATGTACGAGGACAGG-3′ and CEBPD (R): 5′-TGTGATGCTGTTAGAAGGT-3′; PRKDC (F): 5′-CATGGAGAAATCCACCA-3′ and PRKDC (R): 5′-GGCGAGACCACTCAATCA-3′; MCCM (F): 5′-GGTCTCTCATGAGGTTATG-3′ and MCCM (R): 5′-TTCACATCATGGATCC-3′; UBE2V2 (F): 5′-AAGGAGTACGCGAGACCG-3′ and UBE2V2 (R): 5′-ACGGAGAGCTTCTCCGGATG-3′.

Cell viability. For the cell survival assay, THP-1 cells were cultured on 12-well plates. The cells were grown for 24 and 48 h after treatment with bortezomib. Next, the experimental cells were incubated with diluted MTT reagent for 3 h. Subsequently, the samples were spectrophotometrically measured at 595 nm using an enzyme-linked immunosorbent assay plate reader.

TaQMan reverse transcription-PCR for miRNA quantification. Total RNA was isolated using TRizol according to the manufacturer’s instructions, reverse transcribed using the TaqMan microRNA Reverse Transcription Kit and subjected to real-time PCR using the TaqMan microRNA Assay Kit (Applied Biosystems, Waltham, MA, USA).

Plasmids construction and reporter assays. The 5′-flanking region of CEBPD, MAP2K4 (host gene of intronic miR744), SNHG11 (host gene of intronic miR-3182) and miR-3154 were cloned from THP-1 cells using the DNase Tissue Kit (Qiagen, Düsseldorf, Germany) and PCR. The following primers were used for PCR and cloning the 5′-flanking regions: CEBPD (F) (−1938) KpnI – 5′-GGTACCTTTTGTCCTGACAACTTTTTTGG-3′ and (R) (−598) NheI – 5′-GGGAGGCACAACCCACTCGG-3′; MAP2K4 (F) (KpnI) 5′-GGGGTTACCCCGATACACAAATGTTCTTAAAT-3′ and (R) Xhol – 5′-CCGCTCGAACGCGGGTGTTGTGAGAAGG-3′; SNHG11 (F) KpnI – 5′-GGGGTTACCCCGGACAACAGATGAAATTTCC-3′ and (R) Xhol – 5′-CCGCTCGAACGCGGGTGTTGTGAGAAGG-3′. After verification via sequencing, the PCR products were cloned into the multicloning sites of the pGL3-promoter or pGL3-basic vector. These reporter constructs were transfected into 293T cells using TransIT-2020 transfection reagent (Mirus, Madison, WI, USA) according to the manufacturer’s instructions, to generate PcmiMY. These reporter constructs were transfected into 293T cells using TransIT-2020 transfection reagent (Mirus, Madison, WI, USA) according to the manufacturer’s instructions. The transfectants were cultured in complete medium supplemented with HA-CEBPDM or bortezomib. Luciferase activity was measured in the lysates of the transfectants.

Western blot assay. Cells were harvested and lysed in modified RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP40, 0.25% sodium deoxycholate, 1 mM DTT, 10 mM NaF, 1 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml pepstatin and 1 mM Na3VO4). Following lysis, the lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using a 12% polyacrylamide gel, and the proteins were transferred to a polyvinylidene difluoride nylon membrane and dodecyl sulfate-polyacrylamide gel electrophoresis using a 12% polyacrylamide gel, and the proteins were transferred to a polyvinylidene difluoride membrane and probed with primary antibodies for target proteins overnight at 4 °C. The target proteins were after incubation with peroxidase-conjugated secondary antibodies for 1 h at room temperature. The signals were revealed using an Enhanced Chemiluminescence Western Blot System (Thermo Scientific, Rockford, IL, USA).

Chromatin immunoprecipitation. ChIP assay was conducted according to Ju-Ming Wang and co-workers. Briefly, THP-1 cells were treated with formaldehydes. The chromatin was subsequently prepared and sonicated to an average size of 500-1000 bp. The DNA fragments were immunoprecipitated with antibodies specific for Ago1, Ago2, SUZ12, EZH2, DNMT1, HP1, CEBPD and control immunoglobulin G at 4 °C for 12-16 h. After the reversal of the crosslinking, the immunoprecipitated chromatin was amplified using primers specific for the regions of the genomic locus of the target genes. The primers are as indicated below. MAP2K4 (F): 5′-CTCCCTTTGAGGTTGCTTCG-3′ and (R): 5′-ACACGAGGAACGGCCGATA-3′; miR-3154 (F): 5′-GACCTGAGACAGGAAG-3′ and (R): 5′-CCGCTCTACTCAGGTTCAGC-3′; SNHG11 (F): 5′-GGTCTCCTTATCCCAAGAATTT-3′ and (R): 5′-AAGTCTTCTGTAAGGAAGAA-3′; A (F): 5′-AGAAATGGTGGTAGGAGCGTC-3′ and (R): 5′-GGTAGTGTTGCTCGAGT-3′; B (F): 5′-GGCAGAACAACTCGTTTCAC-3′ and (R): 5′-ATGAGGGTTATGGTTGCTGC-3′; C (F): 5′-TATTTCTGCTGGCCCGGTCT-3′ and (R): 5′-GGGCTCTCTGTTGTTAGTCATGA-3′; D (F): 5′-CCCCGGTTCAACAGGAAGTCCTC-3′ and (R): 5′-AAGATTTGAGGCGCCGAGGGG-3′.

Co-immunoprecipitation. The lysates of 293T cells were prepared using an immunoprecipitation lysis buffer (50 mM NaCl, 0.5% NP40 and 10 mM Tris-HCl (pH 8.0)). The supernatant was collected and incubated with anti-YY1 antibody at 4 °C for at least 4 h. Protein-A/G agarose beads were added to the lysates, and the mixtures were incubated and rotated at 4 °C for 1 h. The beads were collected using centrifugation and washed three times with modified RIPA buffer. The proteins that were bound to the beads were eluted after adding 2× electrophoresis sample buffer and were subsequently subjected to western blot analysis.

Methylation-specific PCR. After treating the genomic DNA with sodium bisulfite (Zymo Research, Irvine, CA, USA), the DNA was PCR-amplified using primers specific for the methylated sequences. The primers used for the amplification of methylated and unmethylated promoters of CEBPD were designed.
using the MethPrimer website. The primers used were as follows: methylation (F): 5′-AGGTGTTGAATTTTTTTTAGCA-3′; 5′-TTCCATTACCTACACCACTTAAACA-3′; unmethylation (F): 5′-AGGTGTTGAATTTTTTTAGCA-3′; and 5′-TTCCATTACCTACACCACTTAAACA-3′.

Pre-miR-744/3154/3162 and antisense of miR-744/3154/3162-inducible stable cells. Pre-miR-744/3154/3162 were generated by PCR and then inserted into pSaw4.1.pNeo, a tetracycline-inducible system of lentiviral expression vector. The antisense of miR-744/3154/3162 was inserted into pLAS1x3.3aOΔO, a lentiviral expression vector. Stable THP-1 cells containing pre-miR-744/3154/3162 and the antisense of miR-744/3154/3162 were generated by transfecting pLAS.AS3w.aOn.Pbsd lentiviral-expressing cells and parental THP-1 cells, respectively. Dox (1 μg/ml) was used to induce miR-744/3154/3162 expression. IPTG (500 μM) was used to induce antisense of miR-744/3154/3162 expression. The lentiviral expression vectors were obtained from the National RNA Core Facility located at the Genomic Research Center of Institute of Molecular Biology, Academia Sinica (Taiwan).

Statistical analysis. All experiments were repeated at least three times, and the data were analyzed for statistical significance using Student’s t-test in the Prism 5 Software (La Jolla, CA, USA). The data were expressed as the means ± S.E.M. Differences indicated with asterisks were considered statistically significant.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements
This work was supported by Grant No. NHRI-EX105-10422B from the National Health Research Institutes of Taiwan, Grant Nos MOST 105-2321-B-006-029 and MOST 103-2320-B-006-034-MY3 from the Ministry of Science and Technology of Taiwan.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

1. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522–531.

2. Garzon R, Marucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775–789.

3. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404: 293–296.

4. Ghitza Y, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet 2009; 10: 94–108.

5. Younger ST, Pertsemlidis A, Corey DR. Predicting potential miRNA target sites within gene promoters. Bioorg Med Chem Lett 2009; 19: 3791–3794.

6. Gingeras TR. Origin of phenotypes: genes and transcripts. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

7. de Nigris F. Epigenetic regulators: polycomb-miRNA circuits in cancer. Trends Genet 2009; 25: 489–495.

8. Morris KV. RNA-mediated transcriptional gene silencing in human cells. Curr Top Microbiol Immunol 2006; 302: 211–224.

9. Janowski BA, Huffman KE, Schwartz JC, Ram R, Nordsall S, Ramos DS et al. Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat Struct Mol Biol 2006; 13: 787–792.

10. Kim DH, Saetrom P, Snow OJr, Rossi JJ. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci USA 2008; 105: 16230–16235.

11. Liu J, Carmel MA, Rivas FV, Marsden CG, Thomson JM, Song J et al. Argonautel is the catalytic engine of mammalian RNAi. Science 2004; 305: 1437–1441.

12. Meister G. Argonaute proteins: functional insights and emerging roles. Nat Rev Genet 2013; 14: 447–459.

13. Wei Y, Li L, Wang D, Zhang CY, Zen K. Importin 8 regulates the transport of mature microRNAs into the cell nucleus. J Biol Chem 2014; 289: 10270–10275.

14. Wang J, Lu M, Qi C, Cui Q. TransmiRT: a transcription factor-microRNA regulation database. Nucleic Acids Res 2010; 38: D119–D122.

15. Chu YY, Ko CY, Wang WM, Wang SM, Geen PW, Kuo YM et al. Astrocystic CCAAT/enhancer binding protein delta regulates neuronal viability and spatial learning ability via miR-135a. Mol Neurobiol 2016; 53: 4173–4189.

16. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 2002; 365(Part 3): 561–575.

17. Gery S, Tanoeaki S, Hofmann WK, Koppel A, Koffler HP. CEBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene 2005; 24: 1589–1597.

18. Balamurugan K, Sterneck E. The many faces of CEBPdelta and its relevance for inflammation and cancer. Int J Biol Sci 2013; 9: 977–933.

19. Ko CY, Chang WC, Wang JM. Biological roles of CCAAT/enhancer-binding protein delta during inflammation. J Biomed Sci 2015; 22: 6.

20. Ko CY, Hsu HC, Shen MR, Chang WC, Wang JM. Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex. J Biol Chem 2008; 283: 30919–30932.

21. Pan YC, Li CF, Ko CY, Pan MH, Chen PJ, Tsang JT et al. CEBPdelta reverses RB/E2F1-mediated gene repression and participates in HMDB-induced apoptosis of cancer cells. Clin Cancer Res 2010; 16: 5770–5780.

22. Chuang CH, Wang WJ, Li CF, Ko CY, Chou YH, Chou CP et al. The combination of the produgs perforin-CEBPB and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer. Cell Death Dis 2014; 5: e1220.

23. Radch P, Dai H, Mao M, Oehler V, Schelter J, Bruker D et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794–2799.

24. Agrawal S, Hofmann WK, Tidow N, Enrich M, van den Boom D, Koschmieder S et al. The CEBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 2007; 109: 3995–3999.

25. Tidow N, Gorecky DC, Hirst DJ, Druker BJ. CEBP delta in macrophages contributes to immunosuppression and inhibits phagocytosis in nasopharyngeal carcinoma. Sci Signal 2013; 6: ra59.
Bortezomib-induced miRNAs in leukemia
Y-Y Chu et al.

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)